Good day. A bill in Congress aimed at lowering prescription-drug prices would derail biotechnology venture investment, venture capitalists said in a press conference Wednesday. The bill, H.R. 3, would enable Medicare to negotiate with drugmakers for certain expensive and commonly used drugs, and these prices couldn’t exceed 120% of the drug’s average price in a group of international countries, The Wall Street Journal has reported.
Read the source article at Stock Market Quotes and News